For advanced therapy programs, standard histology is insufficient for characterizing complex, multi-organ system toxicities. Board-certified veterinary pathologist review is required to interpret novel findings, differentiate payload effects from delivery vehicle artifacts, and build a robust, IND-ready dataset. This expert analysis contextualizes histological observations with biodistribution and biomarker data, directly de-risking regulatory submissions and supporting an accelerated development timeline.

What defines a “complex” toxicity profile for an advanced therapy?

A: A complex profile involves findings that lack precedent in classical toxicology. This includes multi-organ inflammatory responses, unexpected cellular changes driven by novel mechanisms of action, or adverse events linked to the delivery system (e.g., lipid nanoparticle-associated inflammation) rather than the therapeutic payload itself.

How does expert pathology review differ from standard histology services?

A: Standard histology provides a descriptive report of microscopic findings. Expert veterinary pathology review provides interpretation and context. A board-certified pathologist synthesizes the histology data with all other study endpoints (e.g., clinical pathology, non-target tissue biodistribution) to determine the toxicological significance and its direct impact on the program’s viability for an IND submission.

Which modalities present the most challenging pathology reads?

A: LNP-mRNA and CRISPR-Cas9 ribonucleoprotein complexes often present the most intricate challenges. The delivery vehicles can induce their own biological responses, which must be carefully distinguished from the effects of the mRNA or gene editing components. Interpreting these concurrent biological activities requires specialized expertise.

What is the role of digital pathology and AI in these reviews?

A: Digital pathology platforms enable quantitative analysis of cellular changes, providing objective data to support a pathologist’s interpretation. This technology facilitates secure peer review and the assembly of a comprehensive, defensible data package for regulatory review.

Board-Certified Pathologist Review as an IND De-Risking Strategy

Engaging a board-certified veterinary pathologist with specific experience in cell and gene therapy is a primary de-risking activity for any IND-enabling program. This level of expertise ensures that findings are interpreted correctly within the specific context of your modality and proposed clinical indication. This rigorous analysis is built into our standard 18-24 month IND timeline, preventing costly program delays caused by ambiguous safety data.

Our approach has supported a 100% IND success rate for client programs since 2019, a track record we are proud to continue since the Franklin Biolabs brand launched in 2024. By providing definitive interpretations, we strengthen the overall data package and provide you with the confidence to proceed to the next development milestone.

All in vivo studies are conducted in full compliance with AAALAC and USDA guidelines. We are committed to the principles of the 3Rs (Replacement, Reduction, and Refinement), ensuring the highest ethical standards are applied to all research programs.